First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors

Stopped The study was terminated following an internal review of the company's current research and development portfolio.

Conditions

• Neoplasms, Pancreatic

Interventions

• DRUG: GSK3145095
• DRUG: Pembrolizumab

Sponsor

GlaxoSmithKline

Collaborators

• [object Object]